IM Cannabis (IMCC) Receivables - Net (2019 - 2026)

IM Cannabis (IMCC) posted quarterly Receivables - Net of $5.2 million for Q1 2026, down 32.82% quarter-over-quarter from $7.8 million in Q4 2025.

IM Cannabis (IMCC) Receivables - Net (2019 - 2026) Analysis & Trends

IM Cannabis' Receivables - Net history runs 8 years deep, the most recent figure standing at $5.2 million for Q1 2026.

In Q1 2026, Receivables - Net changed N/A year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (changed N/A YoY), while the FY2025 annual figure was $7.8 million, down 22.84% from the prior year.
Receivables - Net for Q1 2026 stood at $5.2 million, down from $7.8 million in the prior quarter.
The five-year high for Receivables - Net was $17.5 million in Q1 2022, with the low at $4.6 million in Q1 2023.
The 5-year median for Receivables - Net is $8.0 million (2025), against an average of $8.6 million.
The sharpest annual moves came in 2022 and 2023: Receivables - Net surged 131.37% in 2022, then tumbled 73.66% in 2023.
IM Cannabis' Receivables - Net stood at $6.4 million in 2022, then slipped by 12.15% to $5.6 million in 2023, then surged by 75.82% to $9.9 million in 2024, then decreased by 21.27% to $7.8 million in 2025, then plunged by 32.82% to $5.2 million in 2026.
Business Quant data shows IMCC's Receivables - Net at $5.2 million in Q1 2026, $7.8 million in Q4 2025, and $8.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	IM Cannabis	554,496.00	-614,474.17	1.09 Mn

Download Data